Laval-based biopharmaceutical company Acasti Pharma Inc. is currently focused on the development and commercialization of pharmaceutical products meant for treating cardiovascular diseases. The company is now exploring the possibility of strategic partnerships that would aid in the clinical development of CaPre, one of its major products. Having been incorporated in 2002, Acasti Pharma operates out of Canada and continues to generate significant buzz among industry insiders.